MediWound Ltd PT receives Investment Bank Analyst Rating Update
MediWound (MDWD) reported Q2 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.7 million versus the consensus estimate of...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Basic Materials and Healthcare sectors led shares higher. At the close in NYSE, the...
We are initiating coverage on Clal Biotechnology Industries Ltd (TA:CBI), an Israel/Boston-based healthcare investment company with an extensive portfolio incorporating a diverse...
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.